The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

E. Copson; A.M. Shaaban; T. Maishman; P.M. Moseley; H. McKenzie; J. Bradbury; A. Borley; M. Brzezinska; S.Y.T. Chan; J. Ching; R.I. Cutress; I. Danial; B. Dall; M. Kerin; A.J. Lowery; I.R. Macpherson; L. Romics; E. Sawyer; N. Sharmat; T. Sircar; R. Vidya; Y. Pan; D. Rea; UK Inflammatory Breast Cancer Consortium; L. Jones; D.M. Eccles; F. Berditchevski

doi:10.1016/j.breast.2018.09.003

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

E. Copson, A.M. Shaaban, T. Maishman, P.M. Moseley, H. McKenzie, J. Bradbury, A. Borley, M. Brzezinska, S.Y.T. Chan, J. Ching, R.I. Cutress, I. Danial, B. Dall, M. Kerin, A.J. Lowery, I.R. Macpherson, L. Romics, E. Sawyer, N. Sharmat, T. SircarR. Vidya, Y. Pan, D. Rea, UK Inflammatory Breast Cancer Consortium, L. Jones, D.M. Eccles, F. Berditchevski

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

112 Downloads (Pure)

Abstract

Objectives Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK. Materials and methods Patients with IBC diagnosed between 1997–2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes. Result This retrospective review identified 445 patients with IBC accounting for 0.4–1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients. Conclusions This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.

Original language	English
Journal	BREAST
Early online date	15 Sept 2018
DOIs	https://doi.org/10.1016/j.breast.2018.09.003
Publication status	E-pub ahead of print - 15 Sept 2018

Keywords

Inflammatory breast cancer
Breast
Cancer
Large cohort

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2018.09.003

The presentation, management and_COPSON_Firstonline15September2018_GREEN AAM (CC BY-NC-ND)Accepted author manuscript, 1.28 MBLicence: CC BY-NC-ND

Cite this

Copson, E., Shaaban, A. M., Maishman, T., Moseley, P. M., McKenzie, H., Bradbury, J., Borley, A., Brzezinska, M., Chan, S. Y. T., Ching, J., Cutress, R. I., Danial, I., Dall, B., Kerin, M., Lowery, A. J., Macpherson, I. R., Romics, L., Sawyer, E., Sharmat, N., ... Berditchevski, F. (2018). The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. BREAST. Advance online publication. https://doi.org/10.1016/j.breast.2018.09.003

@article{622e33dac7474c5ba3a5d612a3dfc446,

title = "The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review",

abstract = "Objectives Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK. Materials and methods Patients with IBC diagnosed between 1997–2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes. Result This retrospective review identified 445 patients with IBC accounting for 0.4–1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients. Conclusions This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.",

keywords = "Inflammatory breast cancer, Breast, Cancer, Large cohort",

author = "E. Copson and A.M. Shaaban and T. Maishman and P.M. Moseley and H. McKenzie and J. Bradbury and A. Borley and M. Brzezinska and S.Y.T. Chan and J. Ching and R.I. Cutress and I. Danial and B. Dall and M. Kerin and A.J. Lowery and I.R. Macpherson and L. Romics and E. Sawyer and N. Sharmat and T. Sircar and R. Vidya and Y. Pan and D. Rea and {UK Inflammatory Breast Cancer Consortium} and L. Jones and D.M. Eccles and F. Berditchevski",

year = "2018",

month = sep,

day = "15",

doi = "10.1016/j.breast.2018.09.003",

language = "English",

journal = "BREAST",

issn = "0960-9776",

publisher = "Elsevier",

}

Copson, E, Shaaban, AM, Maishman, T, Moseley, PM, McKenzie, H, Bradbury, J, Borley, A, Brzezinska, M, Chan, SYT, Ching, J, Cutress, RI, Danial, I, Dall, B, Kerin, M, Lowery, AJ, Macpherson, IR, Romics, L, Sawyer, E, Sharmat, N, Sircar, T, Vidya, R, Pan, Y, Rea, D, UK Inflammatory Breast Cancer Consortium, Jones, L, Eccles, DM & Berditchevski, F 2018, 'The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review', BREAST. https://doi.org/10.1016/j.breast.2018.09.003

TY - JOUR

T1 - The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

AU - Copson, E.

AU - Shaaban, A.M.

AU - Maishman, T.

AU - Moseley, P.M.

AU - McKenzie, H.

AU - Bradbury, J.

AU - Borley, A.

AU - Brzezinska, M.

AU - Chan, S.Y.T.

AU - Ching, J.

AU - Cutress, R.I.

AU - Danial, I.

AU - Dall, B.

AU - Kerin, M.

AU - Lowery, A.J.

AU - Macpherson, I.R.

AU - Romics, L.

AU - Sawyer, E.

AU - Sharmat, N.

AU - Sircar, T.

AU - Vidya, R.

AU - Pan, Y.

AU - Rea, D.

AU - UK Inflammatory Breast Cancer Consortium

AU - Jones, L.

AU - Eccles, D.M.

AU - Berditchevski, F.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Objectives Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK. Materials and methods Patients with IBC diagnosed between 1997–2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes. Result This retrospective review identified 445 patients with IBC accounting for 0.4–1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients. Conclusions This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.

AB - Objectives Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK. Materials and methods Patients with IBC diagnosed between 1997–2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes. Result This retrospective review identified 445 patients with IBC accounting for 0.4–1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients. Conclusions This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.

KW - Inflammatory breast cancer

KW - Breast

KW - Cancer

KW - Large cohort

U2 - 10.1016/j.breast.2018.09.003

DO - 10.1016/j.breast.2018.09.003

M3 - Article

SN - 0960-9776

JO - BREAST

JF - BREAST

ER -

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this